^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)

    i
    Other names: BMS-986298, BMS-986298/rHuPH20, Opdivo SC, ONO-4538HSC, BMS986298, BMS 986298, ONO4538HSC, ONO 4538HSC
    Associations

    News

    Trials
    Company:
    BMS, Halozyme, Ono Pharmaceutical
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1d
    Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig (clinicaltrials.gov)
    P=N/A, N=200, Completed, Bristol-Myers Squibb
    New trial
    |
    Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    27d
    CheckMate-1533: A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=76, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRAF (B-raf proto-oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel • pemetrexed • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    4ms
    CA2360001: A Phase 1/2 Study of BMS-986482 Alone or Combination Therapy in Participants with Advanced Solid Tumors (2024-516602-28-00)
    P1/2, N=62, Recruiting, Bristol-Myers Squibb Services Unlimited Company
    New P1/2 trial
    |
    Avastin (bevacizumab) • Opdualag (nivolumab/relatlimab-rmbw) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    4ms
    Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer (clinicaltrials.gov)
    P3, N=718, Not yet recruiting, SWOG Cancer Research Network
    New P3 trial
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Lenvima (lenvatinib) • Cabometyx (cabozantinib tablet) • axitinib • ABP 206 (nivolumab biosimilar) • Cdactin-O (CBM588) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    11ms
    A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, Ono Pharmaceutical Co. Ltd | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    12ms
    CheckMate-1533: A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=76, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel • pemetrexed • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    12ms
    CheckMate 67T: A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (clinicaltrials.gov)
    P3, N=632, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Jan 2026 --> May 2027
    Trial completion date • Head-to-Head
    |
    Opdivo (nivolumab) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    1year
    CheckMate-1533: A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=76, Not yet recruiting, Bristol-Myers Squibb
    New P2 trial
    |
    cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel • pemetrexed • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    1year
    A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations (clinicaltrials.gov)
    P2, N=100, Active, not recruiting, Bristol-Myers Squibb | Trial primary completion date: Aug 2025 --> Apr 2025
    Trial primary completion date
    |
    Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    1year
    CheckMate 67T: A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (clinicaltrials.gov)
    P3, N=632, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed • Head-to-Head
    |
    Opdivo (nivolumab) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    over1year
    CA236-0001: A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=413, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • Opdualag (nivolumab/relatlimab-rmbw) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    over1year
    A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations (clinicaltrials.gov)
    P2, N=100, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)